BDSX (Biodesix) 5-Year EBITDA Growth Rate: 48.40% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BDSX Biodesix Inc BDSX
51 GF Score
Price $26.74
GF Value $21.13
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Biodesix 5-Year EBITDA Growth Rate?

Biodesix BDSX -0.50% 51 5-Year EBITDA Growth Rate is 48.40% as of Jun. 2026. GuruFocus rates BDSX with a GF Score™ of 51/100 and a GF Value™ of $21.13 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Biodesix's EBITDA per Share for the three months ended in Jun. 2026 was $-0.51.

During the past 3 years, the average EBITDA Per Share Growth Rate was 50.80% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 48.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of Biodesix was 52.80% per year. The lowest was -30.90% per year. And the median was 44.20% per year.

Biodesix  (NAS:BDSX) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Biodesix 5-Year EBITDA Growth Rate Related Terms

BDSX vs MYGN, XGN, IMDX: 5-Year EBITDA Growth Rate Comparison

For the Diagnostics & Research subindustry, Biodesix's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biodesix 5-Year EBITDA Growth Rate vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Biodesix's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Biodesix's 5-Year EBITDA Growth Rate falls into.


BDSX
51GF Score
Biodesix Inc BDSX
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biodesix 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 48.40% mean?
Biodesix (BDSX) has a 5-Year EBITDA Growth Rate of 48.40% as of Jun. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Biodesix and its competitors.
Is Biodesix's 5-Year EBITDA Growth Rate too high?
Biodesix's current 5-Year EBITDA Growth Rate is 48.40%. Overall, Biodesix has a GF Score™ of 51/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biodesix's 5-Year EBITDA Growth Rate compare to MYGN and XGN?
Biodesix's 5-Year EBITDA Growth Rate of 48.40% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Medical Diagnostics & Research company?
A good 5-Year EBITDA Growth Rate depends on the Medical Diagnostics & Research industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Biodesix and its competitors. Biodesix's current 5-Year EBITDA Growth Rate is 48.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biodesix stock overvalued right now?
Based on GuruFocus' analysis, Biodesix (BDSX) is currently considered Modestly Overvalued. The stock's GF Value™ is $21.13, compared to a current price of $26.74 — trading 26.5% above its estimated fair value. The current 5-Year EBITDA Growth Rate is 48.40%. Biodesix's overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Biodesix (BDSX), the current 5-Year EBITDA Growth Rate is 48.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biodesix (BDSX) Overvalued in 2026?

Based on GuruFocus' analysis, Biodesix stock appears to be overvalued. The current stock price of $26.74 is trading 26.5% above its estimated GF Value™ of $21.13. GuruFocus considers Biodesix to be Modestly Overvalued.

Key valuation signals for BDSX:

  • 5-Year EBITDA Growth Rate: 48.40%
  • GF Value™: $21.13 vs. price of $26.74 (26.5% above fair value)
  • GF Score™: 51/100 with 5 warning signs

No single metric tells the full story. See the BDSX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biodesix Business Description

Address 919 West Dillon Road, Louisville, CO, USA, 80027
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.
51GF Score

Get the complete analysis for BDSX

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.74
Price
$21.13
GF Value